Institutional profile: Community for Open Antimicrobial Drug Discovery – crowdsourcing new antibiotics and antifungals
Open Access
- 1 May 2017
- journal article
- Published by Future Science Ltd in Future Science OA
- Vol. 3 (2), FSO171
- https://doi.org/10.4155/fsoa-2016-0093
Abstract
The Community for Open Antimicrobial Drug Discovery (CO-ADD) is a not-for-profit, collaborative approach to discovering new antibiotics. We access novel chemical diversity from academic synthetic chemists, who collectively possess millions of untested compounds with chemical diversity that lie outside commercial collections. We perform high-throughput antimicrobial screening of pure compounds derived from both synthetic and natural sources free of charge. The resulting data can be used by participants for publication, patenting and development purposes, and is fed back into the research community through an open-access database after a 2-year period during which information is kept confidential to the provider. CO-ADD is fundamentally asking two questions: can the community work together to address the global threat of antimicrobial resistance; and are there as yet undiscovered, novel antimicrobial compounds already present within our diverse global chemistry community?Keywords
This publication has 5 references indexed in Scilit:
- Antibiotics in the clinical pipeline at the end of 2015The Journal of Antibiotics, 2016
- Chemical philanthropy: a path forward for antibiotic discovery?Future Medicinal Chemistry, 2016
- A systematic review and critical assessment of incentive strategies for discovery and development of novel antibioticsThe Journal of Antibiotics, 2015
- A community-based approach to new antibiotic discoveryNature Reviews Drug Discovery, 2015
- Helping Chemists Discover New AntibioticsACS Infectious Diseases, 2015